![]() | Up a level |
Mian, Afsar Ali, Haberbosch, Isabella, Khamaisie, Hazem, Agbarya, Abed, Pietsch, Larissa, Eshel, Elizabeh, Najib, Dally, Chiriches, Claudia, Ottmann, Oliver, Hantschel, Oliver, Biondi, Ricardo M., Ruthardt, Martin and Mahajna, Jamal
2020.
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K.
Annals of Hematology
Item availability restricted. |
![]() |
Mian, Afsar A., Baumann, Ines, Liebermann, Marcus, Grebien, Florian, Superti-Furga, Giulio, Ruthardt, Martin, Ottmann, Oliver G. and Hantschel, Oliver
2019.
The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.
Leukemia
33
, pp. 2319-2323.
10.1038/s41375-019-0468-y
![]() |
![]() |
Kidan, Noa, Khamaisie, Hazem, Ruimi, Nili, Roitman, Shay, Eshel, Elizabeth, Dally, Najib, Ruthardt, Martin and Mahajna, Jamal 2017. Ectopic expression of snail and twist in Ph+ leukemia cells upregulates CD44 expression and alters their differentiation potential. Journal of Cancer 8 (19) , pp. 3952-3968. 10.7150/jca.19633 |
|
Ratzon, Einav, Najajreh, Yousef, Salem, Rami, Khamaisie, Hazem, Ruthardt, Martin and Mahajna, Jamal 2016. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study. BMC Cancer 16 , 140. 10.1186/s12885-016-2182-8 |
|
Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia, Ottmann, Oliver, Ruthardt, Martin and Mian, Afsar 2016. BCR: a new target in resistance mediated by BCR/ABL-315I? Genes & Cancer 7 (1-2) , pp. 36-46. |
![]() |
Mian, A. A., Rafiei, A., Haberbosch, I., Zeifman, A., Titov, I., Stroylov, V., Metodieva, A., Stroganov, O., Novikov, F., Brill, B., Chilov, G., Hoelzer, D., Ottmann, O. G. and Ruthardt, M. 2015. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia 29 (5) , pp. 1104-1114. 10.1038/leu.2014.326 |
![]() |
Radich, Jerry, Rafiei, Anahita, Mian, Afsar Ali, Doering, Claudia, Metodieva, Anna, Oancea, Claudia, Thalheimer, Frederic B., Hansmann, Martin Leo, Ottmann, Oliver and Ruthardt, Martin 2015. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive Acute Lymphatic Leukemia. PLOS Genetics 11 (4) , e1005144. 10.1371/journal.pgen.1005144 |
![]() |
Mian, Afsar A., Haberboseh, Isabella, Kidan, Noa, Khamaisic, Hazem, Regev, Ofer, Nickola, Meshel, Gal, Maayan, Bloch, Etai, Ratiei, Anahita, Silani, Daryuseh, Ottmann, Oliver, Biondi, Ricardo, Ruthardt, Martin and Mahaina, Jamal 2015. Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. International Journal of Molecular Medicine 36 , S26-S26. |
![]() |
Roos, Jessica, Oancea, Claudia, Heinssmann, Maria, Khan, Dilawar, Held, Hannelore, Kahnt, Astrid S., Capelo, Ricardo, la Buscato, Estel, Proschak, Ewgenij, Puccetti, Elena, Steinhilber, Dieter, Fleming, Ingrid, Maier, Thorsten J. and Ruthardt, Martin 2014. 5-lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia. Cancer Research 74 (18) , pp. 5244-5255. 10.1158/0008-5472.CAN-13-3012 |
![]() |
Beissert, Tim, Hundertmark, Alena, Kaburova, Velina, Travaglini, Lorena, Mian, Afsar A., Nervi, Clara and Ruthardt, Martin 2008. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. International Journal of Cancer 122 (12) , pp. 2744-2752. 10.1002/ijc.23467 |
![]() |